Abstract
Objective: We propose to characterize the extract of YM and to evaluate if the consumption of YM provides a beneficial effect on the survival of dopaminergic neurons in parkinsonian mice.
Background: The clinical signs of Parkinson’s disease (PD) are a consequence of the degeneration of the dopaminergic neurons in the substantia nigra. Since the mechanisms that underlie this neuronal degeneration have not been fully clarified, currently there is no preventive therapy for PD. However, an inverse association was found between coffee intake or smoking and the occurrence of PD. Similarly, a case-control study conducted in Argentina in 2013 revealed that consumption of ‘mate’ also has an inverse association with the risk of developing PD. Mate is a drink widely consumed in several South American countries, made with yerba mate (YM), obtained from the plant Ilex paraguariensis.
Design/Methods: The extract of YM was obtained by ‘cebada simulada’ and the main bioactive compounds caffeine, theobromine, chlorogenic acid and rutin were quantified by HPLC. Wild type mice were lesioned unilaterally with 6-OHDA in the striatum and treated and received water or ‘mate’ as their only source of fluid. During the treatment, locomotor activity was evaluated in open field (OF) session and the striatal tissue was processed by immunohistochemistry for TH to evaluate the degree of dopaminergic denervation.
Results: The infusion of YM was well accepted by the animals. Mice that drink mate have a hyperlocomotor behavior in relation to control during OF session. The protocol of denervation obtained induces a lesion between 31 and 57%. Mice treated with YM have a density of striatal TH+ remaining fibers higher than the control mice.
Conclusions: These results could contribute to the development of novel therapeutic interventions, using YM in association with the frequently used antiparkinsonian drugs and to have thus a direct impact on the quality of life of patients.
Disclosure: Dr. Tribbia has nothing to disclose. Dr. Gomez has nothing to disclose. Dr. Cura has nothing to disclose. Dr. Rivero has nothing to disclose. Dr. Bernardi has nothing to disclose. Dr. Ferrario has nothing to disclose. Dr. Baldi-Coronel has nothing to disclose. Dr. Gershanik has nothing to disclose. Dr. Gatto has nothing to disclose. Dr. Taravini has nothing to disclose.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg